MSLN and ovarian serous adenocarcinoma: However, a larger study of conventional lentivirally transduced anti-mesothelin specific CAR T-cell therapy (CD3-zeta, 4-1-BB) in serous ovarian cancer, pancreatic adenocarcinoma, and malignant pleural mesothelioma showed limited clinical activity [90].